Hefei Lifeon Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of pharmaceutical preparations and active pharmaceutical ingredients in China and internationally. The company offers active pharmaceutical ingredients, which includes felodipine, urea, paeonol, doxazosin mesylate, prilocaine, nifedipine, azilsartan kamedoxomil, methylphenidate hydrochloride, dexmethyl...
Hefei Lifeon Pharmaceutical reported revenue of 1.55 billion CNY for fiscal year 2025, up 2.3% from fiscal year 2024, and net income of 165.19 million CNY. In Q1 2026 (the quarter ended March 31, 2026) revenue was 357.10 million CNY, down 0.9% from a year before. Its largest business segment, Pharmaceutical Industry, brought in 93% of segment revenue in fiscal year 2024; China was the largest region with 100%.
Figures from company filings; latest fiscal year ended December 31, 2025.
No profile data available.